HR Execs on the Move

Avicanna

www.avicanna.com

 
Avicanna is a diversified and vertically integrated Canadian bio-pharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments. Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna`s team of experts have developed and commercialized several industry leading product lines, including: Pura H&W™: an advanced and clinically tested line of CBD ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.avicanna.com
  • 5600 – 110 King Street West
    Toronto, ON CAN M5X 1A9
  • Phone: 647.956.5218

Executives

Name Title Contact Details
Andrea Bartlett
Vice President of People Profile

Similar Companies

MitoSciences Inc

MitoSciences Inc is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PooPrints

We offer a solution to unscooped dog waste. Using our DNA Dog Waste Management program, more than 7,000 communities worldwide have successfully eliminated unscooped dog poop, leading to increased resident satisfaction and an enhanced pet experience. Clients report a 95% reduction in pet waste once our service is implemented because PooPrints is the only foolproof accountability method.

BioShield Technologies

BioShield Technologies is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Rare Cancer Research Foundation

The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.

Pulmotect

Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body`s innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens.